Wockhardt Decides To Exit US Generic Pharma Segment

NDTV Profit

Published On

14 Jul 2025, 11:02 PM IST

Last Updated On

14 Jul 2025, 11:02 PM IST

Wockhardt has initiated strategic realignment of US operations to focus on innovative portfolio. The company has filed for voluntary liquidation of its US arms Morton Grove Pharma and Wockhardt USA.

Add us to your Preferences

Set as your preferred source on Google

RECOMMENDED FOR YOU

Cipla Recalls Over 20,000 Packs Of Inhalation Drug In US

timelogo

Wockhardt Eyes ‘Healthy Bottom Line’ In Coming Quarters Amid US Tariff Concerns

timelogo

Combination Of Factors To Determine Impact Of Trump Tariff On Indian Exports: MoS Finance

timelogo

Wockhardt To Exit US Generic Business; Focus On Antibiotics, Diabetes Care

timelogo